Ortin Global Ltd
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.[1]
- Market Cap ₹ 9.57 Cr.
- Current Price ₹ 11.8
- High / Low ₹ 23.0 / 9.57
- Stock P/E
- Book Value ₹ 2.44
- Dividend Yield 0.00 %
- ROCE -25.1 %
- ROE -36.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 4.83 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -72.0% over past five years.
- Promoter holding is low: 1.23%
- Company has a low return on equity of -35.8% over last 3 years.
- Contingent liabilities of Rs.24.3 Cr.
- Company has high debtors of 279 days.
- Promoter holding has decreased over last 3 years: -14.4%
- Working capital days have increased from 613 days to 1,524 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
67.00 | 60.29 | 62.72 | 61.57 | 79.63 | 167.51 | 197.36 | 8.16 | 8.23 | 6.00 | 2.01 | 0.34 | 0.25 | |
60.90 | 53.80 | 56.83 | 56.12 | 74.22 | 160.83 | 191.66 | 6.92 | 7.85 | 5.47 | 6.40 | 1.23 | 1.15 | |
Operating Profit | 6.10 | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.70 | 1.24 | 0.38 | 0.53 | -4.39 | -0.89 | -0.90 |
OPM % | 9.10% | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.20% | 4.62% | 8.83% | -218.41% | -261.76% | -360.00% |
0.81 | 0.00 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | -1.98 | 0.06 | 0.02 | |
Interest | 3.72 | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.40 | 0.48 | 0.00 | 0.01 |
Depreciation | 1.51 | 1.64 | 1.65 | 1.70 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 | 0.01 | 0.00 |
Profit before tax | 1.68 | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | -0.53 | -0.11 | -7.08 | -0.84 | -0.89 |
Tax % | 29.17% | 32.33% | 41.01% | 55.75% | 0.00% | 30.43% | 181.69% | -623.08% | -24.53% | -18.18% | 13.56% | 1.19% | |
1.19 | 0.90 | 0.83 | 0.50 | 0.68 | 1.28 | -0.56 | 0.95 | -0.40 | -0.09 | -8.04 | -0.85 | -0.92 | |
EPS in Rs | 0.70 | 0.53 | 0.49 | 0.30 | 0.40 | 0.76 | -0.33 | 1.17 | -0.49 | -0.11 | -9.89 | -1.05 | -1.14 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -40% |
5 Years: | -72% |
3 Years: | -65% |
TTM: | -73% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -16% |
3 Years: | % |
TTM: | 88% |
Stock Price CAGR | |
---|---|
10 Years: | -4% |
5 Years: | -10% |
3 Years: | -20% |
1 Year: | -42% |
Return on Equity | |
---|---|
10 Years: | -2% |
5 Years: | -14% |
3 Years: | -36% |
Last Year: | -36% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 |
Reserves | 5.02 | 5.50 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | -5.31 | -6.15 |
18.68 | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.80 | 0.25 | |
31.93 | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 2.05 | 1.55 | |
Total Liabilities | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.67 | 3.78 |
23.90 | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 | 0.00 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.35 | 0.40 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0.00 | 0.00 |
Investments | 0.03 | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
48.64 | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.66 | 3.78 | |
Total Assets | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.67 | 3.78 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1.76 | -1.38 | 0.52 | 1.94 | 1.56 | 6.52 | 3.30 | 18.03 | 2.15 | -0.25 | -4.79 | -0.41 | |
-0.02 | 0.22 | -0.86 | -1.26 | -0.90 | -3.27 | -3.09 | 0.07 | -0.13 | 0.01 | 12.00 | 0.00 | |
0.97 | 1.73 | 0.27 | -0.82 | 0.07 | -2.89 | -1.33 | -9.86 | -0.47 | 0.90 | -3.49 | 0.33 | |
Net Cash Flow | -0.81 | 0.58 | -0.07 | -0.14 | 0.73 | 0.37 | -1.12 | 8.25 | 1.55 | 0.66 | 3.72 | -0.09 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 116.69 | 103.77 | 53.13 | 90.35 | 100.15 | 82.43 | 68.71 | 174.90 | 143.69 | 208.05 | 321.42 | 279.12 |
Inventory Days | 162.92 | 192.30 | 148.72 | 158.21 | 152.21 | 100.07 | 117.80 | 169.10 | 136.29 | 279.94 | 4.92 | 34.76 |
Days Payable | 197.95 | 151.09 | 24.82 | 108.10 | 143.09 | 145.12 | 155.80 | 123.82 | 61.88 | 166.89 | 7.87 | 69.52 |
Cash Conversion Cycle | 81.66 | 144.97 | 177.04 | 140.45 | 109.28 | 37.38 | 30.70 | 220.17 | 218.10 | 321.10 | 318.47 | 244.36 |
Working Capital Days | 3.16 | 29.00 | 16.24 | 37.29 | 41.48 | 16.82 | 11.24 | -87.22 | -109.10 | -43.19 | 357.74 | 1,524.41 |
ROCE % | 13.08% | 12.07% | 10.92% | 9.57% | 9.44% | 11.77% | 8.94% | 3.24% | 1.58% | 1.80% | -40.58% | -25.11% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2d
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct - 38th AGM held 30 Sep 2025; three resolutions passed; 199,162 votes cast.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep - 38th AGM on 30.09.2025; adopted FY2024-25 financials; director reappointment; secretarial auditor appointment.
-
Closure of Trading Window
25 Sep - Trading window closed from 01.10.2025 until 48 hours after unaudited results for quarter/half year ending 30.09.2025.
-
Notice Of 38Th AGM Of The Company Scheduled To Be Held On 30.09.2025
8 Sep - AGM on 30 Sept 2025; annual report filed; secretarial auditor appointed (FY2025-30), fee Rs.50,000.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
OLL is engaged in the manufacturing and trading of pharmaceuticals, drugs, and Intermediates and is also engaged in real estate.